Plain-English translation of NCT07355868 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing , a new treatment made from special stem cells that can regenerate lung tissue. Researchers will give these cells to people with COPD (a chronic lung disease that makes breathing difficult) through an IV infusion to see if the treatment is safe and whether it helps patients breathe better. The trial will start with small doses and gradually increase them to find the right amount.
COPD is a serious lung disease that damages the airways and makes it hard to breathe—it's the third leading cause of death worldwide. Current treatments can help manage symptoms but don't repair the underlying lung damage. This medication aims to address that gap by regenerating damaged lung tissue, potentially offering a new way to help COPD patients.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the stem cell treatment at the study clinic, starting with a low dose that will gradually increase as the researchers monitor your safety and response. You'll need to visit the clinic for screening tests, the infusion itself, and follow-up visits to check how you're doing, including breathing tests and six-minute walk tests. The study will carefully track how you feel, any side effects, and whether your lung function improves over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China